




RealRate

PHARMACEUTICAL 2017

Bristol Myers Squibb CO
Rank 139 of 308

Bristol Myers Squibb



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Bristol Myers Squibb CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bristol Myers Squibb CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Bristol Myers Squibb CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 28% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	13,704,000
Cost of Goods Sold	0
Intangible Assets	8,260,000
Liabilities, Current	8,841,000
Liabilities, Non-Current	6,999,000
Other Assets	6,763,000
Other Compr. Net Income	-85,000
Other Expenses	5,069,000
Other Liabilities	1,520,000
Other Net Income	0
Other Revenues	19,427,000
Property and Equipment	4,980,000
Research and Development	4,940,000
Selling, General and Administrative Expense	4,911,000

Output Variable	Value in 1000 USD
Assets	33,707,000
Liabilities	17,360,000
Expenses	14,920,000
Revenues	19,427,000
Stockholders Equity	16,347,000
Net Income	4,507,000
Comprehensive Net Income	4,464,500
BaseVar	42,749,500
ECR before LimitedLiability	157%
Economic Capital Ratio	273%